Albuminomics

Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis

3 min read

Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis

Bibliographic info

  • Authors: Javier Fernández, Joan Clària, Alex Amorós, Ferrán Aguilar, Miriam Castro, Mireia Casulleras, Juan Acevedo, Marta Duran-Güell, Laura Nuñez, Montserrat Costa, + 27 additional authors including Rajiv Jalan, Mauro Bernardi, Richard Moreau, Vicente Arroyo (EF CLIF Consortium)
  • Journal: Gastroenterology, 2019
  • Institution: Hospital Clínic Barcelona / IDIBAPS / CIBERehd; multiple centers (EF CLIF Consortium)

Key question

Does albumin infusion (20% solution) — in addition to its oncotic effect — also improve hemodynamics, reduce portal pressure, and attenuate systemic inflammation in patients with decompensated cirrhosis?

Methods

Pilot-PRECIOSA Study (hemodynamics + inflammation, non-infection)

  • Design: Prospective, 18 patients with decompensated cirrhosis without bacterial infection
  • Intervention: Low dose (1 g/kg body weight every 2 weeks) vs high dose (1.5 g/kg every week) of 20% albumin solution over 12 weeks
  • Measurements: Serum albumin, plasma renin, cardiocirculatory function, portal pressure (HVPG), plasma cytokines (large panel)
  • Key finding: IL-6 markedly suppressed during albumin treatment → immunomodulatory effect suggested

INFECIR-2 Study (bacterial infection + albumin)

  • Design: Phase 4 RCT; EASL-CLIF Consortium; n=118 randomized; Hospital Clínic, Barcelona; Sep 2014 – Dec 2016
  • Intervention: Antibiotics alone (n=57) vs antibiotics + albumin (1.5 g/kg day 1 + 1 g/kg day 3) (n=61)
  • Disease: Decompensated cirrhosis + acute bacterial infections (unrelated to SBP)
  • Biobanked samples: cytokine levels at D1 (pre-albumin), D3, D7

Main findings

  1. IL-6 markedly suppressed by albumin infusion in Pilot-PRECIOSA — strongest immunomodulatory signal; other cytokines also reduced
  2. Circulatory dysfunction extremely unstable in Pilot-PRECIOSA patients: intense, reversible peaks in renin — suggests dynamic hemodynamic instability not captured by simple pre/post measurements
  3. Hemodynamic effects: albumin treatment improved effective volemia markers; portal pressure trends (HVPG) assessed
  4. INFECIR-2: albumin + antibiotics combination showed favorable cytokine profile vs antibiotics alone at D3/D7
  5. Non-oncotic anti-inflammatory effect confirmed: reduction in inflammatory cytokines during albumin treatment, beyond what can be explained by volume expansion alone
  6. Variability of response: some patients showed transient worsening before improvement — heterogeneous response

Clinical context

  • Disease: Decompensated Liver fibrosis / cirrhosis (with and without bacterial infection)
  • Implication: Albumin infusion in decompensated cirrhosis has anti-inflammatory effects via its non-oncotic properties — not just fluid management. This supports the therapeutic role of restoring functional albumin.
  • Regulatory context: INFECIR-2 is an EASL-CLIF investigator-promoted RCT; high evidence level for antibiotic + albumin combination in bacterial infection

Connections

  • HSA — albumin therapy; non-oncotic properties in CLD
  • Liver fibrosis / decompensated cirrhosis — therapeutic context
  • spinella-2016-review — reviews the non-oncotic effects tested here
  • bernardi-2023 — eAlb perspective; albumin quality as therapeutic target
  • china-2018 — parallel RCT showing albumin counteracts PGE2-mediated immune suppression
  • alcaraz-quiles-2018 — mechanism: oxidized albumin drives cytokine storm; albumin infusion provides functional albumin that dilutes oxidized forms

Take home notes

  • This paper is the clinical proof that albumin infusion has anti-inflammatory effects beyond oncotic pressure. The IL-6 suppression in Pilot-PRECIOSA is the most compelling signal.
  • The hemodynamic instability finding (intense renin peaks) is methodologically important: simple before/after measurements may miss dynamic fluctuations in circulatory function — longitudinal monitoring is needed.
  • INFECIR-2 is an important RCT for the DILI/infection context — albumin + antibiotics improves cytokine profile in infected decompensated cirrhosis patients.
  • The connection to china-2018 (PGE2/albumin) and alcaraz-quiles-2018 (oxidized albumin drives inflammation) forms a mechanistic triangle: oxidized albumin → inflammation; functional albumin → anti-inflammatory; albumin infusion provides functional albumin → restores anti-inflammatory capacity.

Graph View

Backlinks